Abstract
Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequent causes of adverse drug reactions, particularly in patients with asthma and chronic idiophatic urticaria. Many subjects report cutaneous and/or respiratory symptoms and, less frequently, anaphylactic shock after the administration of one (single-reactors) or different (cross-reactors) drugs of this class. Diagnosis: There are no reliable cutaneous or in vitro tests which allow NSAID hypersensitivity to be identified in patients with cross-reactive reactions; therefore, the challenge test is considered the “gold standard” for establishing or excluding a diagnosis of NSAID hypersensitivity in such patients. Management: Culprit drugs should always be avoided by patients with suspected or well-established multiple hypersensitivity to NSAIDs. The therapeutic options range from the administration of alternative drugs – such as weak cyclooxygenase (COX)-1 inhibitors and/or preferential or highly selective COX-2 inhibitors to desensitization to the culprit ones. Conclusion: In patients with different NSAID-induced reactions, the challenge test with both culprit drugs and alternative ones is the only method to establish a reliable diagnosis of NSAID hypersensitivity and to find some alternative therapeutic options, respectively. In specific cases, drug desensitization can also be performed. However, further studies are required to improve management of such patients.
Keywords: Nonsteroidal anti-inflammatory drugs, cross-reactivity, hypersensitivity, challenge test, desensitization
Current Pharmaceutical Design
Title: Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs
Volume: 14 Issue: 27
Author(s): Marinella Viola, Donato Quaratino, Francesco Gaeta, Gabriele Rumi, Cristiano Caruso and Antonino Romano
Affiliation:
Keywords: Nonsteroidal anti-inflammatory drugs, cross-reactivity, hypersensitivity, challenge test, desensitization
Abstract: Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequent causes of adverse drug reactions, particularly in patients with asthma and chronic idiophatic urticaria. Many subjects report cutaneous and/or respiratory symptoms and, less frequently, anaphylactic shock after the administration of one (single-reactors) or different (cross-reactors) drugs of this class. Diagnosis: There are no reliable cutaneous or in vitro tests which allow NSAID hypersensitivity to be identified in patients with cross-reactive reactions; therefore, the challenge test is considered the “gold standard” for establishing or excluding a diagnosis of NSAID hypersensitivity in such patients. Management: Culprit drugs should always be avoided by patients with suspected or well-established multiple hypersensitivity to NSAIDs. The therapeutic options range from the administration of alternative drugs – such as weak cyclooxygenase (COX)-1 inhibitors and/or preferential or highly selective COX-2 inhibitors to desensitization to the culprit ones. Conclusion: In patients with different NSAID-induced reactions, the challenge test with both culprit drugs and alternative ones is the only method to establish a reliable diagnosis of NSAID hypersensitivity and to find some alternative therapeutic options, respectively. In specific cases, drug desensitization can also be performed. However, further studies are required to improve management of such patients.
Export Options
About this article
Cite this article as:
Viola Marinella, Quaratino Donato, Gaeta Francesco, Rumi Gabriele, Caruso Cristiano and Romano Antonino, Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs, Current Pharmaceutical Design 2008; 14 (27) . https://dx.doi.org/10.2174/138161208786369740
DOI https://dx.doi.org/10.2174/138161208786369740 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advancements in the Therapeutics of Food Allergy
Recent Patents on Food, Nutrition & Agriculture “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Perception of Symptoms in Hypertensive Patients and the Relevance to the Application of Anti- Hypertensive Drug Therapy
Current Pharmaceutical Design Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Current Cardiology Reviews The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology Antivenoms for Snakebite Envenomings
Inflammation & Allergy - Drug Targets (Discontinued) Target Product Selection - Where Can Molecular Pharming Make the Difference?
Current Pharmaceutical Design Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
Current Clinical Pharmacology Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Designing Peptidomimetics
Current Topics in Medicinal Chemistry Basophil Activation Test with Indomethacin to Assess Hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs: A Preliminary Study
Inflammation & Allergy - Drug Targets (Discontinued) Antibodies Against Complement System in SLE and their Potential Diagnostic Utility
Current Rheumatology Reviews C1-Inhibitor: Structure, Functional Diversity and Therapeutic Development
Current Medicinal Chemistry Macrolides Allergy
Current Pharmaceutical Design New Strategies and Drugs in the Treatment of Hypertension: Monotherapy or Combination?
Recent Patents on Cardiovascular Drug Discovery Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design An Update on Disease Modifying Antirheumatic Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacogenomics in Aspirin Intolerance
Current Drug Metabolism Role of ARBs in the Blood Hypertension Therapy and Prevention of Cardiovascular Events
Current Drug Targets